AMM 365: Galderma’s Aesthetic Revolution: Sculptra, Restylane, and Relabotulinumtoxin A
March 04, 2025
This episode covers the latest advancements in dermatology as Galderma unveils compelling interim results from their clinical trial at the J.P. Morgan Healthcare Conference. The trial evaluates a novel combination of Sculptra with Restylane Lyft or Contour to address facial volume loss from medication-induced weight loss, showing a 90% patient satisfaction rate. Gerry Muhle from Galderma discusses the rising aesthetic demands driven by weight-loss medications and the company’s commitment to innovation. The episode also introduces RelabotulinumtoxinA, a new neuromodulator poised to impact the cosmetic industry, highlighting the evolving role of clinicians in supporting aesthetic and weight goals.
Quick Takes
- Galderma announces promising interim results from their clinical trial
- Unique combination of Sculptra with Restylane Lyft or Contour targets facial volume loss
- Introduction of Relabotulinumtoxin A expected to revolutionize the cosmetic industry
Episode Transcript
On this February 21, 2025, let’s dive into some groundbreaking news from the world of dermatology. Galderma has just announced promising interim results from their latest clinical trial, showcased at the J.P. Morgan Healthcare Conference. This trial explores a unique combination of Sculptra with Restylane Lyft or Contour, tackling facial volume loss due to medication-driven weight loss. Excitingly, there’s a reported 90% satisfaction rate among patients who have already experienced significant improvements in facial shape, contour, and skin quality.
Gerry Muhle, head of Global Product Strategy at Galderma, elaborated on the growing aesthetic demands stemming from weight-loss medications. Galderma is addressing these needs with ongoing innovations and research, highlighting the importance of both aesthetic and weight-management outcomes.
What’s also intriguing is Galderma’s introduction of Relabotulinumtoxin A, a neuromodulator expected to make waves in the cosmetic industry. Muhle calls on clinicians to play a pivotal role in this transition, supporting patients in achieving both aesthetic and weight goals. And with this thrilling update, we’re witnessing a revolution in treatment options for those undergoing such transformative changes.